Why Do People Relapse After Opioid Detox?
DeBinge opioid transition: When travelling to DeBinge in The Bahamas for OLANI treatment, there is no requirement to complete a separate opioid-free waiting window before arrival. DeBinge uses a medically supervised 4-to-5-day buprenorphine transition. Buprenorphine is introduced to bridge the patient away from full-agonist opioids, stabilised and tapered over the first several days, and the O’Neil Long-Acting Naltrexone Implant is typically inserted around day 4 or 5 while buprenorphine is still being tapered. The planned overlap continues as buprenorphine clears and the implant gradually releases naltrexone. This pathway is clinician-supervised because mistimed naltrexone exposure can precipitate withdrawal.
Based on DeBinge’s clinical experience in The Bahamas since 2018, the implant typically provides its strongest craving and relapse-prevention support on average 9 months, while clinically meaningful opioid-receptor blockade may persist for longer, in some patients up to about 15 months. This longer blockade may continue to reduce opioid effects and overdose risk.
Ongoing recovery: The implant is not a cure. The DeBinge programme includes a full year of professional counselling after implantation to address the behavioural and psychological side of addiction.
Opioid detox can help a person move through withdrawal and become opioid-free, but detoxification does not automatically treat all of the factors involved in opioid use disorder. Cravings, learned triggers, emotional pressure, reduced tolerance, mental-health symptoms and a return to familiar environments can continue after withdrawal has ended.
People can return to opioid use after detox because withdrawal management addresses only one part of opioid use disorder. Once detox ends, the person may still experience cravings, conditioned responses to people and places, stress, pain, emotional distress and access to opioids.
The period after detox can also carry serious overdose risk because opioid tolerance may decrease during abstinence. For this reason, detox should usually be followed by a continuing evidence-based treatment plan rather than treated as the end of care.
Related: If relapse risk is highest during the transition out of opioid use, our guide explains how patients can move toward naltrexone without relying on an unsupported opioid-free waiting period.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an evidence-informed educational resource and is awaiting formal clinical approval. Until that process has been completed, it should not be described as medically reviewed.
View Dr Fergus Law’s professional profile
Why Detox Alone May Leave Important Relapse Risks Untreated
One of the most important distinctions in opioid treatment is the difference between getting through withdrawal and treating opioid use disorder over time.
Detoxification can have an important medical role. It helps manage the transition away from opioids and the physical symptoms that may occur when repeated opioid exposure stops.
But opioid use disorder involves more than withdrawal.
Someone can complete detox, begin sleeping and eating better and no longer experience the most intense physical symptoms while still remaining vulnerable to cravings, stress, familiar cues and opportunities to obtain opioids.
Current CDC guidance states that detoxification on its own, without medication treatment for opioid use disorder, is not recommended because it increases the risk of returning to opioid use, overdose and overdose death.
Detox addresses withdrawal. Continuing treatment addresses what happens after withdrawal has ended.
In This Guide
- Detox versus continuing treatment
- Why cravings can continue
- Learned opioid cues
- Reduced tolerance and overdose
- Returning to the same environment
- Mental health and stress
- Early relapse warning signs
- Medication after detox
- Naltrexone after detox
- Preventing opioid relapse
- Post-detox self-check
- Frequently asked questions
- Clinical sources
Opioid Detox and Opioid Addiction Treatment Are Not the Same Thing
Detoxification focuses primarily on the transition away from opioids and management of withdrawal. Treatment for opioid use disorder is broader and may continue for months or longer depending on the individual.
| Area | Opioid Detox | Continuing OUD Treatment |
|---|---|---|
| Main purpose | Manage withdrawal and transition away from opioids. | Reduce continuing opioid-use risk and support recovery. |
| Timeframe | Usually relatively short. | May continue for months, years or longer according to clinical need. |
| Cravings | May improve but can continue or return. | Craving management becomes part of ongoing treatment. |
| Medication | Medication may be used during withdrawal management. | Buprenorphine, methadone or naltrexone may be considered for OUD treatment. |
| Triggers | Exposure may be limited in a controlled environment. | Real-world triggers need to be identified and managed. |
| Environment | The person may temporarily leave their normal environment. | The recovery plan must work when normal life resumes. |
| Overdose prevention | Tolerance may begin to decrease. | Naloxone, reduced tolerance and overdose planning remain important. |
The key question after detox is therefore not simply whether withdrawal has ended.
It is: what treatment is now in place to reduce the risk of returning to opioids?
Cravings Can Continue After Withdrawal Has Ended
Physical withdrawal and craving are related, but they are not the same thing.
A person may no longer have the most obvious withdrawal symptoms and still experience a powerful urge to use opioids.
Cravings can become connected with:
- stress and emotional pressure;
- pain;
- anxiety or low mood;
- loneliness;
- insomnia;
- relationship conflict;
- boredom;
- people associated with previous opioid use;
- locations where opioids were previously obtained or used;
- memories of opioid effects.
It is a reason to use the recovery plan prepared before the craving becomes overwhelming.
Read more about cravings after rehab and continuing recovery support .
The flagship guide also explains how opioid cravings fit into a wider relapse-prevention strategy .
People, Places and Emotions Can Remain Connected With Opioid Use
Repeated opioid use can become associated with particular routines, emotions, relationships and environments.
These learned associations do not automatically disappear when detox is completed.
People
Seeing someone connected with previous opioid use can activate memories and urges.
Places
Particular streets, homes or neighbourhoods can remain strongly associated with use.
Emotions
Stress, sadness, anger or rejection may previously have been followed by opioid use.
Pain
Physical discomfort may be particularly challenging where opioids were previously connected with pain relief.
Money
Payday or sudden access to money may have become part of the previous pattern.
Routine
A particular time of day or sequence of events may have become connected with opioid use.
This is why identifying opioid relapse triggers before returning to ordinary life can be an important part of prevention.
Reduced Opioid Tolerance Can Make Relapse More Dangerous
Regular opioid exposure can produce tolerance. After opioids are stopped, that tolerance can decrease.
A person who later returns to an amount they previously used may therefore be exposed to substantially greater overdose risk.
Regular Use
Opioid tolerance may increase.
Detox
Regular opioid exposure stops.
Abstinence
Tolerance may decrease.
Return to Use
A previous amount may now have stronger effects.
Overdose Risk
Respiratory depression can become life-threatening.
Where opioid exposure remains possible, overdose education and access to naloxone should form part of recovery planning.
Read more about reduced tolerance and overdose risk after opioid detox .
Detox May End, but the Previous Environment Can Still Be Waiting
During detox, access to opioids may be restricted and daily life may temporarily become more structured.
Returning home can reintroduce many of the same pressures that existed before treatment.
- previous opioid-using contacts;
- suppliers or easy drug access;
- relationship problems;
- financial pressure;
- work stress;
- loneliness;
- unstructured time;
- alcohol or other substance use;
- familiar places connected with opioid use.
Recovery planning therefore needs to ask not only whether detox was completed, but whether daily life after detox actually supports recovery.
Mental-Health Symptoms and Stress May Still Need Treatment
For some people, opioid use has become connected with anxiety, depression, trauma-related symptoms, insomnia, loneliness, chronic stress or emotional pain.
Removing opioids does not automatically resolve those problems.
Appropriate psychological or psychiatric assessment can therefore be an important part of continuing relapse prevention.
Early Warning Signs That Risk May Be Increasing
- cravings becoming more frequent or intense;
- missing counselling or medical appointments;
- stopping medication without clinical guidance;
- increasing isolation;
- returning to previous opioid-using relationships;
- contacting previous suppliers;
- returning to high-risk locations;
- increasing alcohol or other substance use;
- worsening sleep;
- worsening anxiety, depression or emotional distress;
- thinking increasingly about previous opioid effects;
- believing that one episode of use can now be controlled safely;
- abandoning recovery routines that had previously helped.
These signs do not prove that opioid use will occur. They indicate that the current recovery plan may need attention.
Medication Can Be an Important Part of Treatment After Detox
In the United States, FDA-approved medications for opioid use disorder include buprenorphine, methadone and naltrexone.
They work differently and should not be treated as interchangeable.
Buprenorphine
Buprenorphine can reduce withdrawal symptoms and opioid cravings and can be continued as ongoing OUD treatment.
Methadone
Methadone is an established treatment for opioid use disorder and can reduce withdrawal and cravings.
Naltrexone
Naltrexone blocks opioid receptors rather than activating them and requires appropriate opioid-free preparation before initiation.
Treatment choice depends on clinical circumstances, current opioid exposure, previous treatment, patient preferences, access to care and other individual factors.
See the broader comparison in medication options for opioid relapse prevention .
Where Can Naltrexone Fit After Opioid Detox?
Naltrexone is different from methadone and buprenorphine because it is an opioid receptor antagonist.
When adequate naltrexone levels are present, it can block or substantially reduce the effects of opioids.
However, naltrexone should only be started after an appropriate opioid-free period. Starting naltrexone while significant physical opioid dependence remains can precipitate withdrawal.
The required opioid-free period depends on the opioids involved and the individual’s clinical circumstances. This should be determined by an appropriately qualified clinician.
Trying to overcome opioid receptor blockade with larger quantities of opioids can be dangerous. Overdose vulnerability can also increase as blockade declines after a period of reduced opioid tolerance.
What About Long-Acting Naltrexone Implants?
Sustained-release implant formulations are designed to maintain naltrexone exposure for longer periods and may reduce reliance on repeated daily medication decisions.
Longer-acting medication does not replace counselling, mental-health treatment, environmental changes, family involvement or overdose planning.
Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States. Evidence, formulation and intended duration can differ between implant products.
Learn more in the DeBinge Long-Acting Naltrexone Implant Guide .
How Can Opioid Relapse After Detox Be Prevented?
No strategy can guarantee that opioid use will never return. Relapse risk can, however, be addressed through multiple layers of continuing treatment and recovery planning.
Continue treatment after detox
Avoid treating withdrawal management as the final stage of OUD treatment.
Discuss evidence-based medication
Buprenorphine, methadone or naltrexone may be considered depending on individual circumstances.
Identify personal triggers
Record the specific people, environments, emotions and situations connected with previous opioid use.
Create a response for cravings
Decide before the craving occurs who will be contacted, where the person can go and which environments should be left.
Address mental health
Depression, anxiety, trauma, insomnia and other psychiatric concerns should be treated where indicated.
Review the recovery environment
Reduce unnecessary access to opioids and reconsider relationships or locations strongly associated with previous use.
Keep naloxone available
Reduced tolerance after abstinence can make opioid return-to-use especially dangerous.
Plan what happens if opioid use returns
A return to use should trigger safety assessment and treatment re-engagement rather than automatic abandonment of recovery.
Continue With the Complete Opioid Relapse-Prevention Guide
This article explains why relapse can occur after detox. The flagship DeBinge guide covers the next step: building a practical prevention strategy around medication, cravings, triggers, counselling, mental health, family support, naloxone and early response if opioid use returns.
Respond Quickly Rather Than Assuming All Progress Has Been Lost
If a person uses opioids after detox, immediate safety comes first.
Reduced tolerance may increase overdose risk, particularly when someone returns to an amount similar to what they used before detox.
Give naloxone if available, contact emergency services immediately and remain with the person until professional help arrives.
After immediate safety has been addressed, reconnect with treatment quickly and review what changed before opioid use returned.
Plan Treatment Beyond Detox
DeBinge provides addiction treatment in Nassau, The Bahamas. For suitable patients considering antagonist treatment, assessment may include discussion of long-acting naltrexone alongside counselling and continuing recovery planning.
Treatment suitability cannot be determined from an article. A consultation should consider current opioid use, previous treatments, medications, medical history, withdrawal status, relapse history and recovery goals.
Post-Detox Relapse-Prevention Self-Check
This self-check can help identify parts of a post-detox plan that may deserve further discussion. It does not predict whether someone will relapse and does not determine which treatment or medication is appropriate.
Which Areas of the Recovery Plan Need More Attention?
This tool is educational. Your answers are processed in your browser and are not submitted by this quiz.
Areas to Review With Your Treatment Team
These results do not calculate your probability of relapse and do not recommend a particular medication. They identify areas that may deserve further discussion.
Give naloxone if available and contact emergency services immediately.
Opioid Relapse After Detox: FAQs
Why do people relapse after opioid detox?
Detox addresses acute withdrawal but does not automatically remove cravings, triggers, mental-health problems, learned opioid-use patterns or environmental risks. Continuing treatment remains important after detox.
Is opioid detox enough by itself?
Current CDC guidance does not recommend detoxification alone without medication treatment for opioid use disorder because of increased risks of returning to opioid use, overdose and overdose death.
Why can cravings continue after opioid detox?
Cravings can become connected with stress, emotions, people, places, pain and other cues previously associated with opioid use. Ending acute withdrawal does not necessarily remove these learned responses.
Why is opioid relapse dangerous after detox?
Opioid tolerance can decrease during abstinence. Returning to an amount previously tolerated may therefore carry greater overdose risk.
Which medications can be used to treat opioid use disorder?
FDA-approved medications for opioid use disorder include buprenorphine, methadone and naltrexone. Treatment suitability requires individual clinical assessment.
Does everyone need naltrexone after detox?
No. Naltrexone is one treatment option. Buprenorphine or methadone may be more appropriate for some patients, while others may consider antagonist treatment after suitable opioid-free preparation.
Does naltrexone guarantee that cravings will disappear?
No. Individual experiences vary. Naltrexone primarily works through opioid receptor blockade and should not be presented as guaranteeing the absence of cravings or relapse.
Are naltrexone implants FDA-approved in the United States?
No. Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States.
Should naloxone still be available after detox?
Where opioid exposure remains possible, naloxone can form an important part of overdose-prevention planning because tolerance may decrease during abstinence.
What should I do if I use opioids again?
Address immediate safety first. If overdose is suspected, give naloxone if available and contact emergency services. Then reconnect with the treatment team so the recovery plan can be reassessed.
Can opioid relapse after detox be prevented?
No treatment can guarantee that opioid use will never return. Risk can be addressed through continuing treatment, appropriate medication, craving and trigger planning, counselling, mental-health care, environmental changes, social support, naloxone and early intervention.
Evidence Used in This Guide
CDC — Opioid Use Disorder: Treating
Current CDC guidance on medications for opioid use disorder and why detoxification alone is not recommended as complete OUD treatment.
FDA — Medications for Opioid Use Disorder
FDA information on buprenorphine, methadone and naltrexone as approved medications for opioid use disorder.
SAMHSA — TIP 63: Medications for Opioid Use Disorder
SAMHSA’s Treatment Improvement Protocol covering methadone, buprenorphine, naltrexone and other services that support recovery from opioid use disorder.
SAMHSA — Extended-Release Injectable Naltrexone
SAMHSA clinical guidance addressing extended-release injectable naltrexone as part of opioid-use-disorder treatment.
Clinical recommendations, regulatory status and approved products can change. Patients should confirm current information with their treating clinician and the relevant regulator.
Related: If relapse risk is highest during the transition out of opioid use, our guide explains how patients can move toward naltrexone without relying on an unsupported opioid-free waiting period.
Prepared for Medical Review
Dr Fergus Law, BSc, MBChB, FRCPsych
Consultant Psychiatrist specialising in substance misuse and addiction psychiatry.
This article has been prepared as an educational resource concerning opioid detoxification, relapse risk and continuing opioid-use-disorder treatment. It is awaiting formal clinical approval.
View Dr Fergus Law’s professional profile
This Article Does Not Replace Individual Medical Care
This page provides general educational information. It does not diagnose opioid use disorder, determine treatment suitability or recommend a specific medication for an individual.
Do not abruptly stop methadone, buprenorphine, prescribed opioids or another prescribed medication based on information on this page. Medication transitions and opioid withdrawal can require medical supervision.
Naltrexone should not be initiated while significant opioid physical dependence remains. Appropriate opioid-free preparation and clinical assessment are required.
If someone is unconscious, cannot be awakened, has very slow or stopped breathing, or an opioid overdose is suspected, administer naloxone if available and contact local emergency services immediately.
DeBinge is located in Nassau, The Bahamas. We do not operate a treatment facility in the United States. Naltrexone implant formulations are not FDA-approved for routine clinical use in the United States.